Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Sacramento, California and other locations
Dates
study started
completion

Description

Summary

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

Official Title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Keywords

Compensated Cirrhosis, Nonalcoholic Steatohepatitis, Fatty Liver Disease, NASH, Liver Cirrhosis, Fatty Liver, Non-alcoholic Fatty Liver Disease, Fibrosis, Chenodeoxycholic Acid, Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Obeticholic Acid (OCA) 10 mg, Obeticholic Acid (OCA) 10 mg to 25 mg

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Subjects with a confirmed diagnosis of NASH and a fibrosis score of 4 based upon the NASH CRN scoring system determined by central reading

You CAN'T join if...

  1. Current or past history of a clinically evident hepatic decompensation event, such as ascites, hepatic encephalopathy (HE), or variceal bleeding
  2. Current or past history of CP score ≥7 points
  3. Model for End-stage Liver Disease (MELD) score > 12
  4. ALT ≥ 5 X ULN
  5. Calculated creatinine clearance <60mL/min using Cockcroft-Gault method
  6. Hemoglobin A1c (HbA1c) ≥ 9.5 %
  7. Evidence of other known forms of chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)
  8. History of liver transplant, or current placement on a liver transplant list

Locations

  • University of California, Davis Medical Center
    Sacramento California 95817 United States
  • Kaiser Permanente Sacramento Medical Center
    Sacramento California 95825 United States

Details

Status
accepting new patients
Start Date
Completion Date
Sponsor
Intercept Pharmaceuticals
Links
Sign up for this study
ID
NCT03439254
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 919 people participating
Last Updated